Two retrospective studies involving cohorts of 185 and 468 psoriasis patients that were treated with IL-17 inhibitors (either ixekizumab or secukinumab) reported eczematous eruptions prevalence rates of 2.2% and 5.8%, respectively [81,82]. The gene discussed is IL17A; the disease is psoriasis.